Thymic carcinoma: state of the art review.
Thymic carcinoma is a rare neoplasm with distinct clinical and pathological characteristics. The prognosis is often poor with an aggressive course that belies its numerical rarity. Potentially prognostic factors for survival include histopathologic grade, clinical stage, and resectability of the tumor. Five-year survival rates for all patients are approximately 30-50%, with a significant survival time differential between low-grade and high-grade neoplasms. Owing to the paucity of cases, optimal management of thymic carcinoma has yet to be defined. At present, a multimodality approach involving aggressive surgical resection, platinum-based combination chemotherapeutic interventions, and radiotherapy represent the preferred therapeutic approach. Though our knowledge remains somewhat speculative at present, several scientific, technological and therapeutic innovations may have a potentially significant impact on the future of this disease.
Eng
Tony Y
TY
Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, 78284-7800, USA. tyeng@pol.net
Fuller
Clifton D
CD
Jagirdar
Jaishree
J
Bains
Yadvindera
Y
Thomas
Charles R
CR
D006801:Humans; D009367:Neoplasm Staging / Q000379:methods; D013945:Thymoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D013953:Thymus Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy